Skip to content Skip to sidebar Skip to footer

Biotech Stocks

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

After several years of advancing DMX-200/Qytovra, Dimerix is entering the most consequential chapter of its life. The upcoming blinded statistical powering analysis for ACTION3 is the moment where all of that groundwork will likely pay off. Dimerix has been advancing DMX-200/Qytovra for several years DMX-200 is a targeted anti‑inflammatory therapy designed to block the CCR2 pathway…

ByNick Sundich4 days ago

How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!

Knowing how to read a balance sheet is a key skill investors need to know, because the balance sheet is the most underrated document in an annual report. Most new investors skip straight to earnings - perhaps not knowing how importance the balance sheet is or having an appreciate but not knowing how to read…

ByNick Sundich4 days ago

Botanix Pharmaceuticals (ASX:BOT) lands Piramal API backup, targets 25% to 40% COGS cut

Botanix de-risks Sofdra supply chain with Piramal as second API source Botanix Pharmaceuticals (ASX:BOT) has taken a meaningful step forward in de-risking its supply chain, securing a second API supplier after what had been one of the most significant operational vulnerabilities facing the business. This matters more than it might appear on the surface. Even with…

ByCharlie YouldenApril 16, 2026

The Iran Ceasefire Rally Is On! But Investors Aren’t Responding In the Right Way

Add a new term to your vocabulary: The Iran Ceasefire Rally. The rally on the ASX yesterday, that saw our bourse rise over 2.5% in its best day in several months, occurred amidst a 2 week suspension of hostilities in Iran. And the ASX was not alone with Asian markets and North American futures rallying,…

ByNick SundichApril 9, 2026

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

ASX Biotech Investing has always been the market’s most difficult arena. Yes tech and resources are risky spaces too, but at least a gold explorer can gain just off the back of gold price momentum or activity from neighbouring peers. With biotech it is all on the success of the individual company. The science is extraordinary…

ByNick SundichApril 7, 2026

Here are 7 ASX 200 Stocks Winning During The Iran War…And Aren’t In The Soaring Oil and Gas Space!

Investors asked to name ASX 200 stocks winning during the Iran war would likely think of oil and gas stocks, benefiting from soaring prices. This is not incorrect - oil stocks like Woodside, Santos and Karoon have grabbed the headlines as the obvious beneficiaries of the US-Iran conflict that erupted in late February 2026. However, they'd…

ByNick SundichApril 1, 2026

Here are 5 ASX Stocks That Should Be Merged or Be Acquired, and Why the Logic Is Compelling

Despite the dour state of the markets right now, it could be time for certain ASX stocks that should be merged or be acquired to go ahead. With private equity sitting on nearly USD$440bn in uncommitted capital, a more permissive regulatory environment for smaller deal-making, and a wave of ASX small and mid-caps trading at…

ByNick SundichApril 1, 2026

Here Are 6 Questions Investors Need To Ask About Their Portfolio To Get The Best Possible Returns!

There are hard questions investors need to ask about their portfolio every now and again, because anyone telling you there's such a thing as a 'set and forget' investment is wrong. Markets evolve, company fundamentals shift, and macro conditions change, yet many portfolios are left largely unchecked. The most rational approach is to periodically interrogate…

ByNick SundichMarch 31, 2026

The Mayo Clinic will use 4DX’s CT:VQ and investors are thrilled

Another day, another piece of good news from 4DX Medical (ASX:4DX), today news the Mayo Clinic would be employing the company's technology. Mayo is not the first place where CT:VQ has been deployed, but is easily the highest profile. And investors agree. What are the Best ASX Stocks to invest in right now? Check our buy/sell…

ByNick SundichMarch 25, 2026

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

Rhythm Biosciences' colorectal cancer test ColoSTAT is officially on the market and has made its first sale. In our view, this could mark the beginning of a major few years for this company. What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] ColoSTAT is commercialised, albeit not as investors…

ByNick SundichMarch 18, 2026

the Kick-ass Multipurpose WordPress Theme

Biotech Stocks

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

How To Read a Balance Sheet As An Investor: The 7 Questions Prudent Investors Need to Ask!

Botanix Pharmaceuticals (ASX:BOT) lands Piramal API backup, targets 25% to 40% COGS cut

The Iran Ceasefire Rally Is On! But Investors Aren’t Responding In the Right Way

ASX Biotech Investing In 2026: Investors Are More Aware Of The Hard Lessons, But Have Forgotten The Hidden Rewards Of It

Here are 7 ASX 200 Stocks Winning During The Iran War…And Aren’t In The Soaring Oil and Gas Space!

Here are 5 ASX Stocks That Should Be Merged or Be Acquired, and Why the Logic Is Compelling

Here Are 6 Questions Investors Need To Ask About Their Portfolio To Get The Best Possible Returns!

The Mayo Clinic will use 4DX’s CT:VQ and investors are thrilled

Rhythm Biosciences’ ColoSTAT has been commercialised and the roll out will ramp up fast!

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Biotech Stocks

Add Your Heading Text Here